If you have been reading about Aib substitution and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
In a chain-like biological molecule, such as a protein or nucleic acid, a structural motif is a common three-dimensional structure that appears in a variety of different, evolutionarily unrelated molecules. A structural motif does not have to be associated with a sequence motif; it can be represented by different and completely unrelated sequences in different proteins or RNA.
Eugenol is an allyl chain-substituted guaiacol, a member of the allylbenzene class of chemical compounds. It is a colorless to pale yellow, aromatic oily liquid extracted from certain essential oils especially from clove, nutmeg, cinnamon, basil and bay leaf. It is present in concentrations of 80–90% in clove bud oil and at 82–88% in clove leaf oil. Containing eugenol, clove essential oil is obtained from unopened clove buds. Eugenol has a pleasant, spicy, clove-like scent. The name is derived from Eugenia caryophyllata, the former Linnaean nomenclature term for cloves. The currently accepted name is Syzygium aromaticum.
== I == immunoblot - immunoprecipitation - immunotherapy - IMPDH/GMPR family - in situ hybridization - in vitro translation - indoleacetaldoxime dehydratase - inducer - infologs - inherited - initiation codon - insert - insertion - insertion sequence - intellectual property rights - intergenic - interleukin 40 - intron - inverted repeat - IscR stability element - isopiperitenol dehydrogenase -
=== The Human Betterment Foundation (1929–1942) === The Human Betterment Foundation operated in California from 1929 to 1942. In those years, the foundation specialized in researching eugenic sterilizations effects, providing literary contributions of their findings to the public. The foundation distributed literature, such as this in order to promote the efficacy of sterilizations among socially- Sterilizations during this time were promoted and imposed in state institutions. In the pamphlet, the organization describes that the problem is families living on government assistance or "public charity" use more of the public charity than those families sustaining themselves more by 50 percent. The pamphlet stated that families whose children ended up in state homes were increasingly doubling, at a fast rate. The foundation too states that additional children to the state is a burden, but also that taxation rates were increasing because of more children being in need along with the notion that with more children from unfit parents would increase crime and delinquency rates. And another example of anti-Latino sentiment was with state authorities when dealing with minorities. Immigrants that were feeble minded and at borderline intelligence were of the undesirable type. California's state authorities wrote in a survey conducted by the California State Board of Charities and Corrections that Latinos of low intelligence or mental sanity were of the undesirable types.
Sources: en.wikipedia.org
=== Houston Astros === Bagwell spent his entire major-league career with the Houston Astros. Alongside teammate Craig Biggio, he was associated with the group of Astros players known as the “Killer B’s” during the 1990s and 2000s. From 1994 to 2003, Bagwell and Biggio combined for nine All-Star selections, five Gold Glove Awards, five top-five finishes in Most Valuable Player voting, 689 home runs, 2,485 runs batted in and 3,083 runs scored. During this period, the Astros reached the postseason six times. With an exaggerated and unusual batting style, Bagwell waited for each pitch in a low crouch, with legs wide open and knees bent nearly 90 degrees, appearing as if he was sitting on an invisible bench. He stepped back with his front foot as he began his swing. Next, he would rise from his stance and rotate his hands with the bat forward into his powerful, uppercut swing. "That wide stance keeps him from over striding", Joe Torre observed, "which can be your biggest problem when you're trying to hit for power." The low crouch also shrunk his strike zone, allowing him to walk more often. Standing 6 feet tall (72 inches (180 cm)) and weighing 195 pounds (88 kg), he did not present the image of an imposing, home run-hitting giant that would cause pitchers to be very careful when he batted after he began his major league career.
In Australia, New Zealand, and the United States, it is considered an analog of other illegal drugs and can be controlled under laws similar to the US Federal Analog Act. In September 2011, the US temporarily classified mephedrone as a Schedule I drug, with the classification taking effect in October 2011. This was made permanent in July 2012 with the passage of the Synthetic Drug Abuse Prevention Act (SDAPA).
=== Oxides and oxygen-containing salts === Protactinium oxides are known for the metal oxidation states +2, +4, and +5. The most stable is the white pentoxide Pa2O5, which can be produced by igniting protactinium(V) hydroxide in air at a temperature of 500 °C. Its crystal structure is cubic, and the chemical composition is often non-stoichiometric, described as PaO2.25. Another phase of this oxide with orthorhombic symmetry has also been reported. The black dioxide PaO2 is obtained from the pentoxide by reducing it at 1550 °C with hydrogen. It is not readily soluble in either dilute or concentrated nitric, hydrochloric, or sulfuric acid, but easily dissolves in hydrofluoric acid. The dioxide can be converted back to pentoxide by heating in oxygen-containing atmosphere to 1100 °C. The monoxide PaO has only been observed as a thin coating on protactinium metal, but not in an isolated bulk form. Protactinium forms mixed binary oxides with various metals. With alkali metals A, the crystals have a chemical formula APaO3 and perovskite structure; A3PaO4 and distorted rock-salt structure; or A7PaO6, where oxygen atoms form a hexagonal close-packed lattice. In all of these materials, the protactinium ions are octahedrally coordinated. The pentoxide Pa2O5 combines with rare-earth metal oxides R2O3 to form various nonstoichiometric mixed-oxides, also of perovskite structure. Protactinium oxides are basic; they easily convert to hydroxides and can form various salts, such as sulfates, phosphates, nitrates, etc.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.